QPPV.COM KNOWLEDGE ASSESSMENT

Tislelizumab: Mechanism, Clinical Safety and Pharmacovigilance

Test your understanding of the concepts covered by Tislelizumab: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of information is most appropriate for evaluating suspected immune-mediated colitis?

Stool frequency, blood, abdominal pain, hydration, infection testing and, where performed, imaging or endoscopy Only the number of tislelizumab infusions received Only the patient's baseline haemoglobin Tumour response assessment without gastrointestinal information

Question 2 of 10 A case report states only that a patient with gastric cancer received tislelizumab. Which additional information is most important for determining whether the use can be assessed against the EU label?

The patient's preferred method of contacting the healthcare provider The exact treatment line, tumour setting, PD-L1 result and combination medicines The colour and volume of the infusion bag only The number of previous hospital admissions unrelated to cancer

Question 3 of 10 Which description best characterizes tislelizumab?

A humanised IgG4 monoclonal antibody that blocks PD-1 A small-molecule inhibitor of PD-L1 synthesis A cytotoxic antibody-drug conjugate directed against tumour antigens A recombinant cytokine that directly activates macrophages

Question 4 of 10 Which factor would be most useful when stratifying aggregate reports of suspected immune-mediated events?

Only the reporter's professional title Tumour type, regimen, prior checkpoint exposure, latency, immunosuppressive treatment and outcome Only the geographic location of the infusion centre Only whether the patient received monotherapy at any point

Question 5 of 10 Why is recording prior checkpoint inhibitor exposure relevant in a tislelizumab case?

It can help interpret latency, susceptibility and the clinical context of an immune-mediated event It proves that any subsequent event is caused by prior immunotherapy It replaces the need to document current tislelizumab exposure It is relevant only for manufacturing investigations

Question 6 of 10 A patient develops diarrhoea after several previously tolerated tislelizumab infusions. What is the most appropriate pharmacovigilance interpretation?

The event cannot be immune-mediated because earlier doses were tolerated The timing remains compatible with an immune-mediated event, so diagnostic evaluation and chronology should be preserved The event should automatically be attributed to disease progression Only the most recent infusion date is relevant

Question 7 of 10 What is the correct basis for assessing expectedness of a suspected tislelizumab reaction?

The general biological plausibility of PD-1 blockade alone The product-specific reference safety information applicable to the assessment Whether the event has appeared in any oncology publication Whether the event occurred after treatment discontinuation

Question 8 of 10 Which information is particularly important when reconstructing a suspected tislelizumab-associated pneumonitis case?

Oxygenation, imaging, microbiology, pulmonary history and prior thoracic radiotherapy Only the patient's tumour histology Only whether the patient received a patient alert card The infusion-room temperature and manufacturer of the intravenous line

Question 9 of 10 A patient experiences severe diarrhoea several weeks after the final tislelizumab infusion. What is the most appropriate case-processing approach?

Reject the case because exposure had ended Record it as a potential delayed immune-mediated event and reconstruct the prior exposure and diagnostic timeline Attribute it automatically to an unrelated gastrointestinal illness Record only the date of treatment discontinuation

Question 10 of 10 A patient receiving tislelizumab with chemotherapy develops neutropenia and fever. Which interpretation best reflects the article's approach?

The findings should automatically be labelled immune-mediated The chemotherapy partner and infection risk must be considered alongside any possible immune contribution The event cannot be related to treatment because it occurred during combination therapy The partner medicine should be omitted from the safety narrative

QPPV.com

Tislelizumab: Mechanism, Clinical Safety and Pharmacovigilance

Cookie Settings